Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTL-CEBPA + Sorafenib vs Sorafenib in Advanced HCC (OUTREACH2)
NCT04710641Phase 2Completed
- Sponsor
- Mina Alpha Limited
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 2
01
Overview
A Phase 2 trial of MTL-CEBPA in hepatocellular carcinoma (HCC), sponsored by Mina Alpha Limited. Started Jan 2022; status: completed.
02
Drugs
MTL-CEBPA
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04710641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710641.